1. Home
  2. FATE vs IGA Comparison

FATE vs IGA Comparison

Compare FATE & IGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

HOLD

Current Price

$1.71

Market Cap

125.6M

Sector

Health Care

ML Signal

HOLD

Logo Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest

IGA

Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest

HOLD

Current Price

$9.69

Market Cap

148.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
FATE
IGA
Founded
2007
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
125.6M
148.7M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
FATE
IGA
Price
$1.71
$9.69
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$4.10
N/A
AVG Volume (30 Days)
3.0M
55.0K
Earning Date
05-14-2026
01-01-0001
Dividend Yield
N/A
8.93%
EPS Growth
29.88
N/A
EPS
N/A
N/A
Revenue
$6,646,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$9.21
52 Week High
$2.47
$10.12

Technical Indicators

Market Signals
Indicator
FATE
IGA
Relative Strength Index (RSI) 49.44 51.14
Support Level $0.99 $9.53
Resistance Level $1.94 $9.67
Average True Range (ATR) 0.25 0.09
MACD -0.03 -0.00
Stochastic Oscillator 39.76 32.14

Price Performance

Historical Comparison
FATE
IGA

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest

Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.

Share on Social Networks: